Welcome to our dedicated page for Sintx Technologies SEC filings (Ticker: SINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SINTX Technologies, Inc. filings document an advanced ceramics and biomaterials issuer focused on silicon nitride medical technologies, including formal disclosures on operating results, regulatory communications, capital formation, and governance. Recent Form 8-K reports cover quarterly financial results and Regulation FD disclosures tied to FDA 510(k) activity for silicon nitride foot and ankle medical devices.
The company’s SEC record also includes an at-the-market common stock offering agreement, officer appointment and executive compensation disclosures, and a definitive proxy statement for annual meeting voting. These filings describe board and stockholder matters, material agreements, common stock issuance mechanics, and formal disclosure topics connected to SINTX’s medical-device commercialization and biomaterials platform.
Sintx Technologies reported a grant of 70,000 restricted stock units (RSUs) to Kevin Trask, the company’s Chief Financial Officer, on 09/04/2025. The RSUs were issued under the 2025 Equity Incentive Plan and represent the contingent right to receive one share per RSU upon vesting. Twenty percent of the award vested immediately, and the remainder vests at 20% every six months thereafter. After the grant, Mr. Trask beneficially owns 90,000 shares of common stock.
Kevin Trask, Chief Financial Officer of SiNtx Technologies, Inc. (SINT) filed an Initial Statement of Beneficial Ownership (Form 3) reporting direct ownership of 4,376 shares of common stock and 20,000 restricted stock units (RSUs). The RSUs were granted under the 2020 Equity Incentive Plan, with 25% immediately vested and the remainder vesting over three years. The filing is dated 09/04/2025 and was signed by Kevin Ontiveros by power of attorney.
Kevin Patrick Murphy reports beneficial ownership of 225,914 shares of Sintx Technologies, Inc., representing 8.2% of the outstanding common stock based on an outstanding share count of 2,758,865. The disclosed position consists of 138,957 shares of common stock and 86,957 warrants to purchase common stock, and the filer reports sole voting and sole dispositive power over the full amount. The filing states the securities were not acquired to change or influence control of the issuer. The statement is filed on behalf of an individual reporting person, Kevin Patrick Murphy, who identifies as a U.S. citizen.
Jay M. Moyes, a director of SiNtx Technologies, Inc. (SINT), reported a purchase of 3,000 shares of common stock on 08/26/2025 at a reported price of $3.5854 per share. Following the transaction, he beneficially owns 3,000 shares directly. The Form 4 was signed under power of attorney on 08/27/2025. No derivative transactions or additional holdings were reported.
Gregg R. Honigblum, a Director and Chief Investment Officer of SiNtx Technologies, Inc. (SINT), reported multiple open-market purchases on 08/26/2025. The Form 4 shows ten separate purchases of 5,000 shares each, bringing his total beneficial ownership to 64,000 shares. Purchase prices ranged from $3.60 to $3.75 per share. The filing was signed by an agent on 08/27/2025.
Eric K. Olson, President and CEO and a director of Sintx Technologies, Inc. (SINT), reported four open-market purchases on 08/22/2025. The filings show acquisitions of 3,500 shares at $3.37, 5,000 shares at $3.69, 775 shares at $3.64, and 1,200 shares at $3.67, for a total of 10,475 shares purchased that day. Following these transactions, Mr. Olson beneficially owned 24,975 shares. The Form 4 was signed by an authorized representative on 08/25/2025.
On 22 Jul 2025, SINTX Technologies (SINT) filed a Form 8-K (Item 7.01) to furnish a press release announcing it has submitted a 510(k) application to the U.S. Food & Drug Administration for silicon-nitride foot & ankle medical devices. The disclosure is informational only and is not deemed “filed” for liability purposes. No financial statements, revenue guidance, or cost estimates accompany the submission. While the filing marks a key regulatory milestone that could enable U.S. commercialization, the company did not provide an expected review timeline, market size, or projected financial impact.
SINTX Technologies (NASDAQ:SINT) filed an 8-K announcing a definitive Asset Purchase Agreement signed 23 Jun 2025 with Sinaptic Surgical to acquire substantially all foot-and-ankle implant assets. Consideration is warrants for up to 325,000 SINT shares at $6.30, vesting on FDA 510(k) clearance and cumulative revenue milestones of $2.5-$15 million, and expiring after five years. Sinaptic will also purchase 216,450 shares at $3.465 in a private placement. Upon exceeding $15 million net revenue within four years, Sinaptic earns a 5 % royalty on related sales for two years. Closing is targeted for 1 Jul 2025, subject to customary conditions, and SINTX will file a resale registration within 90 days. The deal provides immediate capital, broadens SINTX’s product pipeline, and aligns future dilution with commercial success.